agt-181
Recombinant proteinexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT02371226)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Alpha-L-iduronidaseSupplementation
IDUA supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- agt-181
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03071341 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2016 | ArmaGen, Inc |
| NCT02597114 | Phase 1 | Nov 1, 2015 | ArmaGen, Inc |
| NCT03053089 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2015 | ArmaGen, Inc |
| NCT02371226 | Phase 1 | Jul 1, 2015 | ArmaGen, Inc |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ArmaGen, Inc | For profit | 4 | 4 | 2 | 2015 |
1 organizations
Page 1 / 1